1. Australia Stocks

  2. •

    Technology

  3. •

    Hardware, Equipment & Parts
dorsaVi Ltd

dorsaVi Ltd

DVL.AX
dorsaVi LtdAU flagAustralian Securities Exchange
0.03
AUD
+0.00
- -
41.99MMarket Cap
dorsaVi Ltd
DVL.AX
(Australian Securities Exchange)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
- -
- -
- -
Revenue per Share
- -
-0.03
-0.11
-0.03
-0.02
-0.02
-0.02
-0.03
-0.01
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.15
0.13
0.09
0.05
0.07
0.05
0.04
- -
0.01
- -
- -
- -
- -
Book Value per Share
0.15
0.13
0.07
0.05
0.06
0.02
0.01
- -
0.01
- -
- -
- -
- -
Tangible Book Value per Share
127
110
76
159
175
185
199
231
301
358
467
548
702
Basic Weighted Avg Shares
- -
1
1
3
3
3
3
2
2
2
2
1
- -
Sales/Revenue/Turnover
- -
-824.01
-613.21
-203.01
-125.21
-159.89
-209.31
-395.33
-164.93
-120.2
-124.93
-131.31
- -
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
- -
Depreciation Expense
- -
-4
-8
-5
-4
-4
-4
-8
-2
-2
-2
-1
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-673.35
-544.1
-173.42
-111.84
-108.56
-159.87
-376.04
-108.52
-65.28
-99.37
-95.66
- -
Profit Margin (%)
18
14
6
7
10
8
3
2
3
1
2
1
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
2
1
- -
- -
- -
- -
LT Debt
18
15
6
9
13
9
6
- -
2
1
2
1
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-21.57
-76.27
-69.66
-37.16
-35.41
-51.05
-208.25
-204.1
-118.76
-195.12
-138.83
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Lingyi iTech (Guangdong) Company (002600.SZ)
Delta Electronics, Inc. (2308.TW)
MLS Co., Ltd (002745.SZ)
DSG Global Inc. (DSGT)
Anritsu Corporation (AITUY)
Shenzhen Yitoa Intelligent Control Co.,Ltd. (300131.SZ)
Business
dorsaVi Ltd develops and sells wearable sensor-based motion analysis technologies for clinical, sports, workplace safety, and research applications. The company offers ViMove+ and ViPerform for clinic and sports solutions including athletic performance assessment, injury risk analysis, physical therapy, and rehabilitation; ViSafe and myViSafe for workplace safety to evaluate manual handling, ergonomic risks, and behavioral changes via self-assessments; and Research+ products with advanced algorithms for biomechanical studies; complemented by telehealth solutions, professional suites, video AI, subscriptions, and replacement parts such as pressure and temperature sensors. Incorporated in 2008 and headquartered in Melbourne, Australia, dorsaVi operates primarily in the United States, Australia, and Europe through two segments—Clinical, which generates the majority of revenue, and Workplace—and commercializes its technologies via direct sales, licenses, or fixed-fee consultancies. In November 2025, dorsaVi acquired a Process-In-Memory neuromorphic IP technology portfolio from Technion Research & Development Foundation Ltd. and Neurofabrica Pty Ltd. for $2.65 million in shares, positioning the company to advance intelligent wearables, robotics, and edge intelligence; it also signed a five-year sales agreement with Select Medical covering over 1,900 U.S. outpatient physical therapy centers.